Key Insights The projected fair value for CureVac is US$5.84 based on 2 Stage Free Cash Flow to Equity CureVac is...
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.